For Forest, Two Launches And Two Filings Planned In 2011 As Patent Cliff Looms
On the heels of a strong quarter, Forest has launched the antibiotic Teflaro and plans to introduce the oral COPD candidate Daxas, later this year pending FDA approval.
On the heels of a strong quarter, Forest has launched the antibiotic Teflaro and plans to introduce the oral COPD candidate Daxas, later this year pending FDA approval.